This analysis looked at how olaparib works as a maintenance therapy for patients with advanced ovarian cancer who had already responded to platinum-based chemotherapy. The study compared olaparib to a placebo or standard care to see how it affected the time before the cancer progressed.
The results showed that olaparib significantly improved progression-free survival. This benefit was even more noticeable in patients with BRCA-mutated tumors or HRD-positive tumors. While there was a general trend toward better overall survival for all patients, the improvement was statistically significant specifically for those with BRCA mutations. Olaparib also helped delay the time patients needed to start subsequent therapies.
Patients taking olaparib did face a higher risk of more severe side effects compared to those who did not. However, there was no significant increase in blood-related side effects. Because the evidence for patients with HRD-negative tumors is limited, the results are most certain for those with specific genetic markers. Patients should talk to their doctors to see if this treatment fits their specific cancer profile.
